Inclusion Criteria:  patient diagnosed with lung cancer and included in a clinical trial between 2017 and 2021 trials were conducted with double reads with adjudication, and assessments were based on RECIST 1.1 guidelines The central reads performed using the same radiological reading platform (LMS; Median Technologies, France)  Exclusion Criteria:  reader evaluation with less than 25 adjudications